CBLL · XBRL financial data
CeriBell financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CBLL's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue from contracts with customers | 65,444 | 89,063 |
| Cost of revenue | 8,694 | 10,789 |
| Gross profit | 56,750 | 78,274 |
| Research and development | 13,562 | 19,143 |
| General and administrative | 33,842 | 44,451 |
| Total operating expenses | 96,459 | 136,676 |
| Operating income (loss) | (39,709) | (58,402) |
| Interest expense | 1,992 | 1,890 |
| Other income (expense) | 2,742 | 6,880 |
| Income tax expense (benefit) | 0 | 0 |
| Net income (loss) | (40,455) | (53,412) |
| Earnings per share, basic USD per share | (3.39) | (1.46) |
| Earnings per share, diluted USD per share | (3.39) | (1.46) |
| Weighted average shares, basic thousands of shares | 11,950 | 36,542 |
| Weighted average shares, diluted thousands of shares | 11,950 | 36,542 |
Balance sheet
CSVFiscal years (CBLL's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 194,370 | 40,476 |
| Marketable securities | — | 118,785 |
| Accounts receivable | 10,878 | 15,053 |
| Inventory | 6,937 | 7,288 |
| Prepaid and other current assets | 3,250 | 2,906 |
| Total current assets | 217,272 | 186,718 |
| Property and equipment, net | 2,313 | 2,030 |
| Right-of-use asset | 2,132 | 2,296 |
| Total assets | 225,412 | 195,803 |
| Accounts payable | 1,143 | 2,838 |
| Accrued liabilities | 10,052 | 14,328 |
| Total current liabilities | 12,989 | 19,190 |
| Lease liability, non-current | 1,314 | 1,360 |
| Total liabilities | 34,247 | 40,467 |
| Accumulated deficit | (166,944) | (220,356) |
| Total stockholders' equity | 191,165 | 155,336 |
| Total liabilities and equity | 225,412 | 195,803 |
| Common shares outstanding (cover page) thousands of shares | 35,868 | 37,641 |
Cash flows
CSVFiscal years (CBLL's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (40,455) | (53,412) |
| Stock-based compensation | 5,411 | 12,223 |
| Depreciation and amortization | 1,141 | 1,341 |
| Net cash from operating activities | (35,043) | (40,808) |
| Purchases of property and equipment | 1,340 | 767 |
| Net cash from investing activities | (1,598) | (118,137) |
| Net cash from financing activities | 196,516 | 5,051 |
| Net change in cash | 159,875 | (153,894) |
Compare with peers
SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Ceribell | 41,989 | 29,341 | (13,078)* | 38.8M | 7.8 quarters | 10-QSep 30, 2026 |
| Delcath Systems | 47,521 | 29,133 | 5,712* | 34.7M | — | 10-QJun 30, 2026 |
| Axogen | 328,888 | 75,834 | 16,536* | 59.7M | — | 10-QSep 30, 2026 |
| Angiodynamics | 33,973 | 80,915 | (15,330) | 42.1M | 2.2 quarters | 10-QAug 31, 2026 |
| Orthofix Medical | 103,810 | 210,933 | (6,224)* | 40.7M | 16.7 quarters | 10-QJun 30, 2026 |
| Pulse Biosciences | 101,620 | 434 | (18,709)* | 71.3M | 5.4 quarters | 10-QJun 30, 2026 |
| Butterfly Network | 122,301 | 32,598 | (2,266)* | not reported | 10.3 quarters | 10-QSep 30, 2026 |
| Orthopediatrics | 17,141 | 72,661 | 4,506* | 26.1M | — | 10-QSep 30, 2026 |
| Iradimed | 63,288 | 24,203 | 6,997* | 12.8M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.